NCT06690138View on ClinicalTrials.gov

A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 15, 2024

Primary Completion Date

February 11, 2025

Study Completion Date

February 11, 2025

Conditions
Healthy Participants
Interventions
DRUG

Divarasib

Divarasib will be administered as a single oral dose as specified for the respective period.

DRUG

Itraconazole

Itraconazole will be administered BID on Day 1 and QD from Day 2 to 13 and as specified for the respective period.

Trial Locations (1)

75247

Dallas Clinical Research Unit, Dallas

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY